Literature DB >> 8620633

Effects of cyclosporin A on bone turnover and on resorption of demineralized bone matrix.

A L Ekelund1, O Nilsson.   

Abstract

The effects of the immunosuppressive drug Cyclosporin A on orthotopic bone turnover and on the resorption of demineralized bone matrix were studied. In the first experiment, rats were labeled with 3H-proline and 45Calcium and treated with Cyclosporin A 2 mg/kg/day or placebo for 2 weeks. Cyclosporin A treatment resulted in an early transient increase in matrix and mineral turnover in the metaphyseal region of the tibia. Furthermore, Cyclosporin A increased mineral turnover in the diaphyseal part of the tibia, but the matrix turnover was unaffected. No osteopenia was seen after 2 weeks. In the second experiment, prelabeled (3H-proline) demineralized bone matrix from rats and rabbits was implanted in the abdominal walls of growing rats that were treated with Cyclosporin A or placebo. After 4 weeks there was no difference in the remaining activity in the implants from Cyclosporin A or placebo treated rats. Cyclosporin A treatment increased mineral content in demineralized allogenic bone matrix implants by 1/3. In the demineralized xenogenic bone matrix implants, mineral content was 4 times higher in the cyclosporin A treated implants.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620633     DOI: 10.1097/00003086-199605000-00015

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Evaluation of Cyclosporine A with β-TCP in the Treatment of Human Infra bony Defects - A Randomized Controlled Pilot Study.

Authors:  Jyotsna Amalakara; Krishnajaneya Reddy; Haritha Avula; Ashank Mishra; Butchibabu Kalakonda; Ruchi Pandey
Journal:  J Clin Diagn Res       Date:  2017-01-01

2.  Orthodontic treatment for a patient with acute myeloid leukemia.

Authors:  Johnson Hsin-Chung Cheng; Tracy Yi-Hsuan Lee; Kai-Liang Jiang; Chih-Yuan Fang
Journal:  J Dent Sci       Date:  2022-04-15       Impact factor: 3.719

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.